BV100 (rifabutin IV) drug interaction studies in healthy subjects with index CYP450 3A probes midazolam and itraconazole Authors: Pierre Delique, Christian Kemmer, Lisa Husband, Géza Lakner, Jürgen Jäger, Françoise Jung, Andrew F Shorr, Glenn E Dale Published: 2026 ABSTRACT AbstractBackgroundBV100 is a novel intravenous (IV) formulation of rifabutin under development for the treatment of serious Acinetobacter baumannii infections. The primary objectives of these studies were to assess potential pharmacokinetic interactions between BV100 and two index cytochrome P450 3A enzymes (CYP3A) probes, midazolam (substrate) and itraconazole (inhibitor), and to evaluate BV100’s safety profile.MethodsTwo open-label Phase 1 studies were conducted in healthy participants. Study 1 evaluated the impact of multiple IV doses of BV100 (300 mg) on the pharmacokinetics of a single oral dose of midazolam (5 mg). Study 2 assessed the impact of repeated oral doses of itraconazole (200 mg) on the pharmacokinetics of a single IV dose of BV100 (300 mg). Pharmacokinetic parameters [maximum plasma concentration (Cmax), area under the plasma concentration–time curve from zero to 24 hours (AUC0–24), area under the plasma concentration–time curve from zero to infinity (AUC0–∞)] were analysed using geometric means and 90% confidence intervals (CI). Drug–drug interactions (DDIs) were defined as a 90% CI outside the equivalence range of 80%–125%.ResultsBoth studies demonstrated DDIs. BV100 increased midazolam metabolism, with Cmax and AUC test/reference ratios of 77% and 53%, respectively. The decreased midazolam AUC (47%) indicated BV100 is a mild/weak CYP3A inducer by EMA/FDA criteria. Itraconazole decreased BV100 metabolism, resulting in increased BV100 exposure (Cmax 1.1-fold; AUC 1.3-1.7-fold), consistent with mild inhibition. BV100 was considered generally safe and well tolerated in both studies, with no serious adverse events reported.ConclusionBV100 is a mild/weak CYP3A enzyme inducer and a mild substrate for CYP3A inhibitors. However, co-administration with strong CYP3A inhibitors resulted in a disproportionate increase in exposure to the active metabolite 25-O-desacetyl rifabutin, leading to an ∼2-fold increase in total active-moiety exposure. Clinical monitoring is advised when BV100 is co-administered with a strong CYP3A inhibitor. BV100 was safe and well tolerated. Introduction Antimicrobial resistance is a major health issue worldwide. Multidrug-resistant Acinetobacter baumannii (A. baumannii) especially carbapenem-resistant A. baumannii (CRAB), has become a concerning pathogen among hospitalized patients.1 Recognizing the urgent need for new therapies, both the World Health Organization and the Center for Disease Control and Prevention have classified CRAB as a top priority pathogen.2,3 Current treatment options for CRAB are limited, the most recent guidance suggests combination therapy for moderate to severe infections and all current treatment options have multiple limitations.4 BV100 is a novel intravenous (IV) formulation of rifabutin currently being developed to address this unmet need in serious CRAB infections.5 Unlike rifampin, rifabutin demonstrates excellent in vitro activity against A. baumannii clinical isolates when tested in iron limited conditions.6,7 Synergy with standard-of-care agents has been demonstrated8,9 and in vivo studies in murine lung infection models with A. baumannii10 further support rifabutin’s therapeutic potential. However, due to the low oral bioavailability and high variability in exposure,11 the currently available oral formulation is not suitable for the treatment of severe CRAB infections, highlighting the need for an IV formulation. The rifamycins (e.g. rifampin, rifabutin) are well-known inducers of CYP3A enzymes, which may affect the metabolism of other hepatically metabolized co-administered drugs.12,13 Rifampin is a strong inducer of CYP3A and is associated with a wider array of drug–drug interactions (DDIs) compared with rifabutin.13 Consequently, oral rifabutin has been widely used for treatment of infections in complex patients, such as those with HIV or non-tuberculous mycobacteria, who require multiple hepatically metabolized medications. Hence, to further characterize BV100, two Phase 1 studies were undertaken evaluating the concurrent IV administration of BV100 and midazolam (an index CYP3A substrate) and itraconazole (an index CYP3A inhibitor). The objectives of these investigations were to determine: (i) the impact of BV100 on the pharmacokinetics (PK) of midazolam and its metabolite, 1-hydroxymidazolam; (ii) the impact of itraconazole on the PK of BV100 and its metabolite 25-O-desacetyl rifabutin and (iii) the safety and tolerability of BV100. Materials and methods Ethics The studies described in this report were conducted in compliance with the International Conference on Harmonisation Good Clinical Practice guidelines and the Declaration of Helsinki. Informed consent was obtained from all participants. The clinical trials.gov identifiers are NCT05537090 (midazolam) and NCT05684718 (itraconazole). Both studies were reviewed and approved by the Medical Research Council Ethics Committee for Clinical Pharmacology (ETT KFEB) and the Medical Research Council Ethics Committee for Clinical Pharmacology (MRC ECCP) in Hungary where the studies were performed. The EudraCT reference numbers are 2022-000938-42 (midazolam) and 2022-001955-18 (itraconazole). Study methodology Two open-label, fixed-sequence Phase 1 studies were conducted separately. In both studies, BV100 was administered as a 300 mg IV infusion over 2 hours. Midazolam and itraconazole were given orally as a syrup (midazolam) or a solution (itraconazole). The first study (Study 1, NCT05537090) evaluated the effect of BV100 on the PK of midazolam and its metabolite 1-hydroxymidazolam. This study was a fixed three-period study. In Period 1, participants received a single 5 mg oral dose of midazolam under fasted conditions. After a washout period of 24 hours, BV100 (300 mg) was administered every 12 hours (q12h) for a total of eight doses to achieve steady state (Period 2). On Day 7 (Period 3), a ninth BV100 dose was given concurrently with a second 5 mg midazolam dose. The second study (Study 2, NCT05684718) evaluated the effect of multiple doses of itraconazole on rifabutin and 25-O-desacetyl-rifabutin PK. This study was divided into two periods. On Day 1 (Period 1), participants received a single BV100 dose (300 mg), followed by a washout period from (Day 2 to Day 7). From Day 8 to Day 21 (Period 2), itraconazole oral solution (200 mg) was administered daily under fasted conditions. On Day 11, a second BV100 dose was given following the itraconazole dose. Eligible participants in both studies were healthy males or females adults (18–55 years), with a body mass index between 19 and 30 kg/m2, and normal renal function defined as an estimated glomerular filtration rate according to Chronic Kidney Disease Epidemiology Collaboration ≥90 mL/min. Key exclusion criteria included receipt of any medications, including St John’s Wort, known to chronically alter drug absorption or elimination processes within 30 days of the first dose administration, regular use of any known inducer of metabolism in the 3 months before the study. Participants with history or evidence of clinically relevant ECG abnormalities or persistent elevations of liver enzymes or creatinine above the upper limit of normal at screening were excluded. The PK analysis population for both studies included participants who received at least one dose of BV100, midazolam or itraconazole and had at least one valid PK measurement. Participants could be excluded from the PK population if they deviated significantly from the protocol or if data were unavailable or incomplete. The safety population for both studies was defined as all participants who received at least one dose of the study medication whether withdrawn prematurely from the study or not. Pharmacokinetic sampling and assay Study 1 A total of 15 plasma samples were collected over 24 hours following midazolam administration to measure concentrations of midazolam and its metabolite 1-hydroxymidazolam, both before (Period 1) and after (Period 3) BV100 dosing. For rifabutin and its metabolite 25-O-desacetyl rifabutin, 21 plasma samples were collected over 72 hours following the start of drug administration after the first (Period 2) and last (Period 3) BV100 dose. Study 2 A total of 19 plasma samples were collected over 144 hours following the first dose of BV100 (Period 1), and 22 samples over 220 hours during repeated itraconazole administration (Period 2). Plasma samples for itraconazole concentration determination were not collected. Drug concentrations in both studies were measured using validated liquid chromatography with tandem mass spectroscopy methodology.14 The lower limits of quantification were 20 ng/mL for rifabutin, 5 ng/mL for 25-O-desacetyl rifabutin, 50 pg/mL for midazolam and 50 pg/mL for 1-hydroxymidazolam. The bioanalytical laboratory assays were performed by Nuvisan GmbH; the methods were validated in accordance with FDA/EMA bioanalytical method validation guidance, and analyte stability (bench-top, freeze–thaw, long-term frozen) was established during validation. Safety assessment Continuous monitoring for adverse events was performed throughout both studies to ensure participant safety along with regular assessment of clinical laboratory evaluations, vital signs, physical examinations (including neurological), local tolerability and 12-lead electrocardiograms. Data analysis PK analyses for both studies were based on actual sampling times and measured drug concentrations. PK parameters were calculated using non-compartmental analysis methods and standard PK equations with WinNonlin v.7 or higher (Certara, NJ, USA). To assess the presence of an interaction, a linear fixed effect model was used. Maximum plasma concentration (Cmax), area under the plasma concentration–time curve from zero to 24 hours (AUC0-24) and area under the plasma concentration–time curve from zero to infinity (AUC0–∞) values were logarithmically transformed and geometric means were calculated. The absence of a DDI was defined as a 90% confidence interval (CI) for the test/reference ratio (BV100 + midazolam or itraconazole versus midazolam alone in Study 1, or BV100 alone in Study 2) falling within the 80%–125% equivalence range, in accordance with FDA guidance.15 FDA and EMA definitions were used to classify the degree of inhibition or induction in each study.15,16 In Study 2, analyses of variance with the log-transformed PK parameters as dependent variables, the factor treatment as fixed effect and participant as random effect were conducted. Only participants having valid parameters for both treatment groups were included in the model. The parameters Cmax and AUC0–24 were statistically analysed for rifabutin and 25-O-desacetyl-rifabutin and the parameter AUC0–∞ (if warranted for a reliable number of cases) for rifabutin only. Results In Study 1, 23 participants were dosed in Period 1, 20 participants were dosed in Period 2, and 17 participants completed the study. Six participants discontinued the study due to consent withdrawal or adverse event. Sixteen participants completed Period 3 and received all treatments according to the protocol. One participant did not receive study drug in Period 3 but completed the study. Twenty-three participants were analysed in both the PK and safety populations. In Study 2, 17 participants were enrolled for safety analysis (Safety population) with 16 included in the PK population; one participant withdrew consent before itraconazole dosing. Overall, most participants enrolled were young males. Demographic details for both studies are shown in Table 1. Table 1.Participant demographics for Study 1 (midazolam) and Study 2 (itraconazole)ParameterStudy 1 (n = 23)Study 2 (n = 17)Age (years)31.2 ± 6.6(20–46)29.2 ± 7.6(18–52)Sex (M)22 (96%)17 (100%)Weight (kg)68.6 ± 11.2(50–92)68.0 ± 11.0(54.5–92.8)BMI (kg/m2)22.7 ± 3.0(19–29.5)23.2 ± 3.2(19.2–29.0)Race (white)23 (100%)17 (100%)All data are presented as mean ± standard deviation, minimum–maximum. Data for gender and race are presented as number of participants and percentage. BMI, body mass index Participant demographics for Study 1 (midazolam) and Study 2 (itraconazole) All data are presented as mean ± standard deviation, minimum–maximum. Data for gender and race are presented as number of participants and percentage. BMI, body mass index PK parameters for midazolam and 1-hydroxymidazolam, with and without BV100 (Study 1), are presented in Table 2, and corresponding concentration–time curves are displayed in Figure 1. Co-administration of BV100 resulted in decreased midazolam AUC and Cmax, indicating increased metabolism. Elimination parameters, clearance (CL) and elimination half-life (t1/2), suggested faster clearance. In addition, the metabolite-to-parent ratio for 1-hydroxymidazolam increased from 0.19 to 0.20 (AUC, +5%) and 0.15 to 0.18 (Cmax, +20%), indicating an effect of concomitant administration of BV100 on the metabolism of midazolam. The 90% CI for both the midazolam Cmax and AUC ratios fell outside the prespecified 80%–125% equivalence range, confirming a DDI (Table 3). The ∼47% reduction in midazolam AUC classifies BV100 as a mild CYP3A inducer by the EMA criteria16 or weak CYP3A inducer by the FDA criteria.15 Table 2.Midazolam and 1-hydroxymidazolam pharmacokinetic parameters on Day 1 (before BV100 administration) and Day 7 (in presence of BV100), expressed as geometric mean (geometric CV%)Parameter N Day 1 N Day 7Midazolam C max (ng/mL)2331.73 (34.5)1624.85 (23.0)AUC0–24 (h*ng/mL)2392.14 (42.9)1649.45 (26.3)AUC0–∞ (h*ng/mL)a1884.51 (41.3)1550.69 (25.8)CL/F (L/h)2353.56 (44.2)16100.72 (26.3) t 1/2 (h)a183.04 (30.5)152.45 (51.2)MRT (h)a183.19 (22.2)152.46 (26.5)1-hydroxymidazolam C max (ng/mL)234.75 (48.9)164.52 (61.5)AUC0–24 (h*ng/mL)2317.19 (41.6)1610.06 (45.9)AUC0–∞ (h*ng/mL)1419.25 (31.1)1210.02 (41.3)CL/F (L/h)23284.53 (41.7)16492.81 (46.8) t 1/2 (h)a143.17 (33.4)122.22 (44.3)MRT (h)a144.43 (21.0)122.94 (25.3)Data are presented as geometric mean (geometric CV%). N, number of participants contributing to each parameter; CL/F, apparent total CL; MRT, mean residence time. Day 1, midazolam administered alone; Day 7, midazolam co-administered with BV100. aEstimated in a reduced number of participants; N is shown per parameter. Midazolam and 1-hydroxymidazolam pharmacokinetic parameters on Day 1 (before BV100 administration) and Day 7 (in presence of BV100), expressed as geometric mean (geometric CV%) Data are presented as geometric mean (geometric CV%). N, number of participants contributing to each parameter; CL/F, apparent total CL; MRT, mean residence time. Day 1, midazolam administered alone; Day 7, midazolam co-administered with BV100. aEstimated in a reduced number of participants; N is shown per parameter. Mean ± standard deviation plasma concentration–time profiles of midazolam and 1-hydroxymidazolam before Day 1 (filled circles) and with BV100 administration at Day 7 (open circles). Table 3.Comparison of geometric means and 90% CIs following administration of midazolam alone or in combination with BV100ParameterMidazolam w/BV100/midazolam w/o BV100 ratio (%)Decrease of AUC (%)90% CI C max 77.11—67.42–88.19AUC0–∞52.6147.3945.23–61.19AUC0–2453.1846.8245.93–61.57 Comparison of geometric means and 90% CIs following administration of midazolam alone or in combination with BV100 PK parameters for rifabutin and 25-O-desacetyl rifabutin before and after itraconazole (Study 2) are shown in Table 4, with concentration–time curves in Figure 2. Systemic exposure of rifabutin increased when administered with itraconazole (Cmax +14% or 1.1-fold, AUC0-24 + 26% or 1.3-fold, AUC0-∞ + 69% or 1.7-fold). Elimination was reduced with CL decreased and t1/2 increased by 41% and 77%, respectively. Systemic exposure of 25-O-desacetyl rifabutin also increased when BV100 was administered with itraconazole with Cmax, AUC0-24, increased by 2.8- and 3.4-fold, respectively. The metabolic ratio (metabolite:parent) for Cmax and AUC0-tlast suggested enhanced metabolism of rifabutin with itraconazole. These effects were more pronounced for the metabolite. Table 4.Rifabutin and 25-O-desacetyl-rifabutin plasma pharmacokinetics before and after itraconazole administration (n = 16)Rifabutin parameterBV100 aloneBV100 + itraconazole C max (ng/mL) Geometric mean10621214 Geometric CV%27.227.7AUC0–24 (h*ng/mL) Geometric mean7662.39647.5 Geometric CV%17.316.5AUC0–∞ (h*ng/mL) Geometric mean11 594.519 547 Geometric CV%19.016.3CL (L/h) Geometric mean25.87415.284 Geometric CV%19.016.5 t ½ (h) Geometric mean27.94249.509 Geometric CV%54.641.625-O-desacetyl-rifabutin Parameter C max (ng/mL) Geometric mean36.33102.1 Geometric CV%36.4029.7 t max (h) median3.9926.000 range2.50–6.054.02–12.00AUC0–24 (h*ng/mL) Geometric mean498.11716.6 Geometric CV%36.730.4MR Cmax Geometric mean0.03420.0843 Geometric CV%39.727.6MRAUC Geometric mean0.05160.3159 Geometric CV%44.333.6 t max, time corresponding to occurrence of maximum plasma concentration; MR, metabolic ratio of parameter of metabolite divided by parameter of parent drug BV100 (MRAUC calculated using AUC zero to time of last measured concentration); CV, coefficient of variation Rifabutin and 25-O-desacetyl-rifabutin plasma pharmacokinetics before and after itraconazole administration (n = 16) t max, time corresponding to occurrence of maximum plasma concentration; MR, metabolic ratio of parameter of metabolite divided by parameter of parent drug BV100 (MRAUC calculated using AUC zero to time of last measured concentration); CV, coefficient of variation Mean ± standard deviation plasma concentration–time profiles of rifabutin and 25-O-desacetylrifabutin before itraconazole administration (filled circles) and with itraconazole administration (open circles). Table 5 displays the ratio and CIs for key rifabutin and 25-O-desacetyl rifabutin PK parameters following administration of BV100 alone or in combination with itraconazole. The two-sided 90% CI for both rifabutin Cmax and AUC ratios were outside the 80%–125% equivalence limits, confirming a DDI when itraconazole and BV100 are administered concurrently. On the basis of the observed degree of inhibition, itraconazole’s impact on BV 100 would be classified as mild/weak.15,16 Table 5.Comparison of geometric means and 90% CIs for rifabutin and 25-O-desacetyl-rifabutin following administration of BV100 alone or in combination with itraconazoleRifabutin parameter N BV100 w/itraconazole/BV100 w/o itraconazole ratio (%)90% CI C max 16114.34103.74–126.03AUC0–2416125.91118.88–133.35AUC0–∞16168.59158.66-179.1425-O-desacetyl-rifabutin parameterTest/reference ratio (%)90% CI C max 15279.18248.75–313.32AUC0–2416344.60305.93–388.15I, itraconazole Comparison of geometric means and 90% CIs for rifabutin and 25-O-desacetyl-rifabutin following administration of BV100 alone or in combination with itraconazole I, itraconazole Across both studies, a total of 40 participants were included in the safety population, 23 in Study 1 and 17 in Study 2. No deaths, serious adverse events or other significant adverse events (AEs) occurred during either study. Outcome for all AEs was recovered/resolved. No clinically relevant effects on clinical laboratory profiles, vital signs, ECG, physical or neurological evaluation were noted. Overall, BV100 was well tolerated. In Study 1, 21 out of 23 participants (91%) reported at least one treatment-emergent AE (TEAE) and 19 (83%) experienced a treatment-related AE. A total of 90 TEAEs were reported. Most were of mild intensity (88%) and 12% were moderate intensity. No TEAEs of severe intensity were reported. The most frequently reported TEAEs in participants were infusion-site reactions (65%), headache (26%) and infusion-site pain (17%). Fifty-one TEAEs in 19 patients were reported as related to BV100. Most frequent were infusion-related reactions in 17 participants and nausea in two participants. All TEAEs considered related to BV100 recovered/resolved at the end of the study. Three participants experienced four TEAEs resulting in BV100 discontinuation. One of these participants experienced two TEAEs that were possibly related to BV100; both events were non-serious, mild in intensity and recovered/resolved by the end of the study. In Study 2, 9 out of 17 participants (53%) experienced at least one AE, with eight participants (47%) reporting TEAEs. Of the 19 TEAEs observed, only 26% were deemed related to BV100, and all were mild in intensity. There were two moderate and no severe TEAEs reported. The only BV100-related TEAEs reported were related to local tolerability. Discussion BV100 is an intravenous formulation of rifabutin currently under development for treatment of serious A. baumannii complex infections, specifically CRAB. CRAB is increasingly recognized as a worldwide threat in seriously ill patients and has been designated as an urgent public health priority by both the Center for Disease Control and Prevention3 and WHO2 underscoring the critical need for new antibiotic therapies. At present, only the oral formulation of rifabutin is commercially available; however, its poor bioavailability limits systemic exposure and efficacy against CRAB, despite excellent in vitro activity. An IV formulation, such as BV100, would be ideal as it expects to increase systemic exposure compared with oral dosing and enhance rifabutin’s concentration-dependent bactericidal activity.17 Rifabutin is metabolized hepatically via the CYP450 enzyme system and, like rifampin, acts as a concentration-dependent enzyme inducer, although its effects are much less pronounced than rifampin, which is a strong inducer.13,18–20 Thus, understanding the degree of enzyme induction is essential, as it contributes to the potential for DDIs that may affect efficacy and safety, particularly in a critically ill population. Therefore, the primary objective in these studies was to investigate the impact of BV100 (IV rifabutin) on the PK of two well-characterized probes, midazolam and itraconazole. Midazolam is a recommended substrate to evaluate the CYP3A induction potential of agents; itraconazole is a recognized inhibitor of CYP3A and is used to assess the impact on the metabolism of compounds of interest. The secondary objective of these studies was to evaluate the safety profile of BV100. Herein we report the results of the studies evaluating concurrent administration of these probes with BV100. In general, BV100 was safe and well tolerated with the most frequent TEAEs were infusion-site reactions (65% of Study 1 participants), consistent with IV administration; these were predominantly mild, non-serious and resolved, but are relevant to clinical use and may be mitigated through attention to regular rotation of peripheral infusion sites, central venous catheter use and limiting BV100 to a maximum tolerated dose. Both studies documented a DDI between BV100 and each probe. BV100 was classified as a mild or weak inducer, depending on the categorization by the EMA or FDA, on the basis of its effect on midazolam pharmacokinetics, with a reduction in midazolam systemic exposure of just under 50%. This degree of induction may affect the clinical effectiveness of other hepatically metabolized drugs, particularly those with a narrow therapeutic index and some caution during therapy is warranted. Itraconazole decreased rifabutin metabolism resulting in a <2-fold increase in systemic exposure, consistent with mild inhibition. Thus, the extent of BV100 accumulation was relatively low. By contrast, the effect was more pronounced for the 25-O-desacetyl metabolite. This may have been due to prolonged length of exposure of parent compound that could increase the amount of metabolite produced or due to possible metabolite formation exceeding metabolite elimination. It should also be noted that itraconazole was administered once daily and that dosing recommendations include both single-daily and twice-daily dosing. Thus, enzymatic inhibition may not be the same as seen with twice-daily dosing. Importantly, BV100 was well tolerated when administered concurrently with itraconazole, and no significant safety concerns were identified. Therefore, since itraconazole is a known strong inhibitor of CYP3A, one would not expect clinical issues with other hepatic inhibitors. However, there are limitations to our findings that should be noted. Namely, these studies were performed in young, healthy, white adult males with normal renal function, a population probably different from seriously ill patients. Moreover, extrapolation of these results to older, seriously ill patients with organ dysfunction and polypharmacy issues (multiple enzyme inhibitors/substrates) should be done with caution. In addition, these studies were performed for a shorter time period and not over prolonged dosing regimens that are often used. Therefore, the reported safety profile may differ in sick patients requiring prolonged exposures as that may increase the occurrence of less frequent AEs such as uveitis that have been documented with longer exposures. However, despite this, these studies report valuable information to assist in the clinical use of BV100. In light of our findings, clinicians can appropriately plan for how to manage the use of BV100 with many often-used molecules that interact with the CYP3A system while caring for patients with severe CRAB infections. Consequently, physicians can not only anticipate potential DDIs but proactively respond should the clinical scenario necessitates some change at the bedside. In conclusion, 300 mg of BV100 was safe and well tolerated when administered either as a single dose with itraconazole or as multiple doses with midazolam, both well-known and recognized CYP3A probes. Clinical monitoring may be warranted when BV100 is co-administered with CYP3A sensitive drugs that have a narrow therapeutic index. These results support the continued development of BV100, with clear drug interaction labelling. Acknowledgements The authors acknowledge the assistance of Scientific and Medical Affairs, LLC in the preparation of this manuscript, which was supported by BioVersys AG, Basel, Switzerland. We thank the CRU Hungary team for excellent work in managing and executing the clinical trial, and Tanja Armengol for project management support. We thank the Nuvisan GmbH team for excellent work in managing and executing the bioanalysis. Contributor Information Pierre Delique, BioVersys SAS, C/o Institut Pasteur de Lille, 1 rue du Professeur Calmette, Lille, France. Christian Kemmer, BioVersys AG, C/o Technologiepark Basel, Hochbergerstrasse 60c, Basel CH-4057, Switzerland. Lisa Husband, BioVersys SAS, C/o Institut Pasteur de Lille, 1 rue du Professeur Calmette, Lille, France. Géza Lakner, CRU Hungary Kft., Göd H-2131, Hungary. Jürgen Jäger, BioVersys AG, C/o Technologiepark Basel, Hochbergerstrasse 60c, Basel CH-4057, Switzerland. Françoise Jung, BioVersys AG, C/o Technologiepark Basel, Hochbergerstrasse 60c, Basel CH-4057, Switzerland. Andrew F Shorr, Pulmonary and Critical Care Medicine, Medstar Washington Hospital Center, 110 Irving St., NW, Washington, DC 20010, USA. Glenn E Dale, BioVersys SAS, C/o Institut Pasteur de Lille, 1 rue du Professeur Calmette, Lille, France; BioVersys AG, C/o Technologiepark Basel, Hochbergerstrasse 60c, Basel CH-4057, Switzerland. Funding These studies were funded by BioVersys AG, Basel, Switzerland. Transparency declaration The results of the Phase 1 studies were presented at ID week in 2024 for Study 1 (poster P1246) and in 2025 for Study 1 and 2 (poster P-1163). G.E.D., C.K., L.H., F.J., J.J. and P.D. are employees of BioVersys AG or SAS, and may hold share/options. A.F.S. has served as a consultant to BioVersys. G.L. has no conflicts of interest to declare. Author contributions Pierre Delique (Conceptualization, Methodology, Writing—review & editing), Christian Kemmer (Conceptualization, Formal analysis, Methodology, Writing—review & editing), Lisa Husband (Conceptualization, Formal analysis, Methodology, Writing—review & editing), Géza Lakner (Project administration, Writing—review & editing), Jürgen Jäger (Project administration, Writing—review & editing), Francoise Jung (Conceptualization, Writing—original draft, Writing—review & editing), Andrew F. Shorr (Formal analysis, Writing—review & editing) and Glenn E Dale (Conceptualization, Formal analysis, Methodology, Writing—review & editing) Data sharing agreement The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. References